Skip to main content
Equibles

Brendan Teehan

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Brendan Teehan

Earlier roles on record: COO at Acadia Pharmaceuticals Inc (ACAD) until November 18, 2024. Acadia Pharmaceuticals Inc reported in an 8-K filed November 20, 2024 that Brendan Teehan was terminated as Executive Vice President, Chief Operating Officer and Head of Commercial, effective November 18, 2024. The proxy statement of Acadia Pharmaceuticals Inc reports total compensation of $2,297,810 for Brendan Teehan in fiscal 2022, including a base salary of $482,521. Disclosed compensation is on record for 2 fiscal years. Brendan Teehan has spoken on 13 earnings calls across 1 company, most recently for Acadia Pharmaceuticals Inc on November 6, 2024.

“On November 18, 2024, Acadia Pharmaceuticals Inc. (the "Company") agreed with Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial that he would be involuntarily terminated without Cause (as such term is defined in the Company's Management Severance Benefit Plan (the "Severance Plan")) from his position, effective immediately.”
Acadia Pharmaceuticals Inc Form 8-K, filed November 20, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Acadia Pharmaceuticals Inc (ACAD) $482,521 $2,297,810
2021 Acadia Pharmaceuticals Inc (ACAD) $393,917 $2,474,115

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Show 2 earlier activities